A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We have undergone significant changes to our business and operations as a result of a series of completed transactions summarized below and discussed in further detail under the next section titled “Recent Developments and Stock Exchange Listing” below. We are also pursuing a new direction, which will have a significant impact on us in the future, which is also discussed below and elsewhere in this annual report. Accordingly, this annual report includes a significant amount of new information about us, our changed business and limited operations, our intended strategic direction and prospects, which will be important to read carefully and understand, as such new information will impact us in the near term and in the future. As a result of completing each of the transactions discussed below, we have significantly reduced our business operations and currently have limited sources of future revenue generation.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 9.8M | 10M | 14M | 10M | 9.9M |
| Net Income | 3.2M | -8.6M | - | -16M | - | -11M |
| EPS | $11.00 | $-12.65 | $-695.70 | $-1,767.50 | $-26,250.00 | $-54.25 |
| Free Cash Flow | -7.1M | -5.2M | -4.3M | -6.8M | -9.2M | -4.7M |
| ROIC | -175.0% | -41934.6% | - | -219.4% | - | -89.6% |
| Gross Margin | - | 66.3% | 58.2% | 54.0% | 63.8% | 60.0% |
| Debt/Equity | 0.13 | -7.75 | 0.00 | 0.00 | 1.36 | 0.11 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -7.7M | -5.8M | -4.1M | -14M | -8.9M | -6.4M |
| Operating Margin | 0.0% | -59.7% | -39.2% | -100.1% | -86.8% | -64.7% |
| ROE | 292.4% | -540.5% | - | -157.0% | - | -166.1% |
| Shares Outstanding | 25M | 1M | 1M | 0M | 0M | 0M |
NovaBay Pharmaceuticals, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 60.5%. At current prices, the estimated annualized return to fair value is -8.3%.
NovaBay Pharmaceuticals, Inc. (NBY) has a 5-year average return on invested capital (ROIC) of -89.6%. This is below average and may indicate limited pricing power.
NovaBay Pharmaceuticals, Inc. (NBY) has a market capitalization of $41M. It is classified as a small-cap stock.
NovaBay Pharmaceuticals, Inc. (NBY) does not currently pay a regular dividend.
NovaBay Pharmaceuticals, Inc. (NBY) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
NovaBay Pharmaceuticals, Inc. (NBY) reported annual revenue of $10 million in its most recent fiscal year, based on SEC EDGAR filings.
NovaBay Pharmaceuticals, Inc. (NBY) has a net profit margin of -88.0%. The company is currently unprofitable.
NovaBay Pharmaceuticals, Inc. (NBY) generated $-5 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
NovaBay Pharmaceuticals, Inc. (NBY) reported earnings per share (EPS) of $-12.65 in its most recent fiscal year.
NovaBay Pharmaceuticals, Inc. (NBY) has a return on equity (ROE) of -540.5%. A negative ROE may indicate losses or negative equity.
NovaBay Pharmaceuticals, Inc. (NBY) has a 5-year average gross margin of 60.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for NovaBay Pharmaceuticals, Inc. (NBY), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
NovaBay Pharmaceuticals, Inc. (NBY) has a book value per share of $-0.19, based on its most recent annual SEC filing.